(Total Views: 195)
Posted On: 11/21/2025 4:58:54 AM
Post# of 8896
The state of operations in my opinion!
Just asked Alexa...Will Electrome and Biel Corporation soon announce their partneship?
Just looking this up..
Yes, Electrome and Biel Corporation have already agreed to collaborate on producing PMF devices. The partnership involves Biel licensing is Pulsed Shortwave Therapy (PSWT) technology to Electrome, which gives Electrome access to clinically validated technology while allowing BIEL to monetize its intellectual property and expand market growth.
Partnership Structure
This collaboration represents a powerful convergence in bioelectronic medicine, combining Electrome's AI-driven discovery platform with BIEL's established therapeutic device infrastructure. The partnership unites the "software" of advanced AI-driven discovery with the "hardware" and infrastructure required for market-ready therapeutic devices.
Strategic implications
Industry analyst's suggest this could be a strategic opportunity, with some recommending that Electrome or other partners consider acquiring a stake in BIEL to capitalize on potential exponential growth.
The collaboration appears to already be in motion rather than a future announcement, positioning both companies to leverage their complementary strengths in the rapidly evolving bioelectronic medicine sector.
WOW THATS A MOUTHFUL!
Just asked Alexa...Will Electrome and Biel Corporation soon announce their partneship?
Just looking this up..
Yes, Electrome and Biel Corporation have already agreed to collaborate on producing PMF devices. The partnership involves Biel licensing is Pulsed Shortwave Therapy (PSWT) technology to Electrome, which gives Electrome access to clinically validated technology while allowing BIEL to monetize its intellectual property and expand market growth.
Partnership Structure
This collaboration represents a powerful convergence in bioelectronic medicine, combining Electrome's AI-driven discovery platform with BIEL's established therapeutic device infrastructure. The partnership unites the "software" of advanced AI-driven discovery with the "hardware" and infrastructure required for market-ready therapeutic devices.
Strategic implications
Industry analyst's suggest this could be a strategic opportunity, with some recommending that Electrome or other partners consider acquiring a stake in BIEL to capitalize on potential exponential growth.
The collaboration appears to already be in motion rather than a future announcement, positioning both companies to leverage their complementary strengths in the rapidly evolving bioelectronic medicine sector.
WOW THATS A MOUTHFUL!
(1)
(0)
